The Kazakh anti-cancer drug has successfully completed the initial stages of testing
An anti-cancer drug developed by Kazakh scientists has successfully passed the first two phases of clinical trials. The scientists plan to complete the project within 2–3 years, reports a Kazinform News Agency correspondent, citing the press service of the Government of Kazakhstan.
Dos Sarbasov, Vice President of the National Academy of Sciences of Kazakhstan and a biology professor at Nazarbayev University (NU), spoke about the development of the anti-cancer drug.
After the initial dose of the drug, the condition of 15 cancer patients stabilized, tumor growth stopped in six individuals, and one patient even showed a reduction in tumor size. Currently, the patients have been administered an increased dose of the drug, following confirmation from medical professionals of its non-toxicity.
“We began testing the anti-cancer drug in 2022–2023 and obtained the necessary approvals. We have completed the first and second phases of clinical trials. Currently, we are administering increased doses. The trials are being conducted at the Kazakh Institute of Oncology and Radiology. The drug targets cancer cells that absorb glucose. Our patent is international. In the control group, the drug demonstrated stabilization: tumors did not grow, and in one patient, the tumor shrank by 30%. We need to see this through to the end — we must complete the project within 2–3 years,” said Dos Sarbassov.
Kazinform News Agency previously reported that Kazakhstani biologist Dos Sarbasov developed a drug aimed at treating patients with stage four cancers.
